- Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status(2020)
Authors: Hasan Baysal, Ines De Pauw, Hannah Zaryouh, Jorrit De Waele, Marc Peeters, Patrick Pauwels, Jan Vermorken, Evelien Smits, Filip Lardon, Julie Jacobs, et al.
Pages: 1 - 10
- Oligometastatic disease management(2020)
Authors: Petr Szturz, Jan Vermorken
- Follow-up of head and neck cancer survivors(2020)
Authors: Petr Szturz, Carl Van Laer, Christian Simon, Dirk Van Gestel, Jean Bourhis, Jan Vermorken
Pages: 1 - 9
- SARS-CoV-2 and cancer(2020)
Authors: Peter Van Dam, Manon Huizing, Gino Mestach, Stazie Dierckxsens, Wiebren Tjalma, Xuan Bich Trinh, Kostantinos Papadimitriou, Sevilay Altintas, Jan Vermorken, Christof Vulsteke, et al.
- Low-dose vs. high-dose cisplatin(2019)
Authors: Petr Szturz, Naomi Kiyota, Makoto Tahara, Kumar Prabhash, Vanita Noronha, David Adelstein, Dirk Van Gestel, Jan Vermorken
- Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck(2019)
Authors: Robert Haddad, Joel Guigay, Ulrich Keilholz, Paul M. Clement, Jerome Fayette, Luciano Souza de Viana, Frederic Rolland, Didier Cupissol, Lionnel Geoffrois, Gabriela Kornek, et al.
Pages: 82 - 91
- In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53(2019)
Authors: Jolien Van den Bossche, Christophe Deben, Ines De Pauw, Hilde Lambrechts, Christophe Hermans, Julie Jacobs, Pol Specenier, Patrick Pauwels, Jan Vermorken, Marc Peeters, et al.
Pages: 1196 - 1213
- Afatinib vs placebo as adjuvant therapy after chemoradiotherapy in squamous cell carcinoma of the head and neck(2019)
Authors: Barbara Burtness, Robert Haddad, Jose Dinis, Jose Trigo, Tomoya Yokota, Luciano Souza de Viana, Ilya Romanov, Jan Vermorken, Jean Bourhis, Makoto Tahara, et al.
Pages: 1170 - 1180
- Evolution of self-perceived swallowing function, tongue strength and swallow-related quality of life during radiotherapy in head and neck cancer patients(2019)
Authors: Leen Van den Steen, Dirk Van Gestel, Olivier Vanderveken, Jan Vanderwegen, Cathy Lazarus, Jean-Francois Daisne, Carl Van Laer, Pol Specenier, Diane Van Rompaey, Steven Marien, et al.
Pages: 2197 - 2207
- Radiosensitization of non-small cell lung cancer cells by the Plk1 inhibitor volasertib is dependent on the p53 status(2019)
Authors: Andreas Domen, Marc Peeters, Ines De Pauw, Julie Jacobs, Sven De Bruycker, Pol Specenier, Patrick Pauwels, Jan Vermorken, An Wouters